EG 427 announces issuance of the first 2 patents for its HSV-based gene therapy treatment.

April 11, 2023
  • Issued European and Japanese patents cover herpes simplex virus (HSV) vectors selectively inhibiting subtype of sensory neurons
  • Related initial therapeutic indications encompass multiple bladder conditions with a first focus on neurogenic detrusor overactivity 

Read full press release in English or in French

< back

Recent posts

EG 427 appoints Ralph Laufer as new member to Board of Directors
EG 427 appoints Ralph Laufer as new member to Board of Directors

read more >

EG 427 announces attendance to multiple upcoming conferences
EG 427 announces attendance to multiple upcoming conferences

read more >

EG 427 Appoints New Members To Board of Directors and Scientific Advisory Board
EG 427 Appoints New Members To Board of Directors and Scientific Advisory Board

read more >

×

By clicking Consent, you accept the saving of all cookie data on your device. If you click Denied, only the data necessary for the website to function is saved. More information about cookies in the privacy policy.

settings Reject I agree
×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.